Research programme: mGluR2 modulators - Addex Pharmaceuticals/Ortho-McNeil

Drug Profile

Research programme: mGluR2 modulators - Addex Pharmaceuticals/Ortho-McNeil

Alternative Names: ADX 92639; JNJ-40068782

Latest Information Update: 07 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Addex Pharmaceuticals; Ortho-McNeil
  • Developer Addex Therapeutics; IRCCS Neuromed Mediterranean Neurological Institute; Ortho-McNeil
  • Class Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cognition disorders; Major depressive disorder; Stroke
  • Discontinued Anxiety disorders; Schizophrenia

Most Recent Events

  • 07 Dec 2016 Discontinued - Preclinical for Anxiety disorders in Europe (unspecified route)
  • 07 Dec 2016 Discontinued - Preclinical for Schizophrenia in Europe (unspecified route)
  • 07 Dec 2016 Preclinical trials in Cognition disorders in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top